RxDoctor Payments Data

Eric Chen, MD

Internal Medicine · Providence, RINPI 1881076156

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 26.7% of the total. Reporting peaked in 2019 at $1,857 and has fallen 97.9% since, to $38 in 2024.

$2,010in general payments, 2019–2025

Across 24 payments — averaging $83.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$538
  • E.r. Squibb & Sons, L.L.C.$330
  • Otsuka America Pharmaceutical, Inc.$225
  • Regeneron Healthcare Solutions, Inc.$120
  • Bristol Myers Squibb$118
  • Takeda Pharmaceuticals U.S.A., Inc.$115
  • plus $565 from 6 others

What the payments were for

  • Food & beverage$2,010100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,010 in reported general payments places this provider in the 85th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island →

Medicare billing

Part B allowed, 2024
$3,997
Medicare patients
16
Services billed
35

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pantoprazole Sodium12$374
Atorvastatin Calcium23$286
Furosemide22$250
Hydralazine Hcl14$212
Amlodipine Besylate15$155
Cefadroxil11$96
Prednisone12$94
Doxycycline Monohydrate12$87
Metoprolol Tartrate12$82

Paid to pharmacies, not to this prescriber.

Other internal medicine in Providence

See the full list for Rhode Island →

Where these figures come from

Is this you, or does something look wrong? →